OneDigital Investment Advisors LLC Purchases 6,511 Shares of Novo Nordisk A/S (NYSE:NVO)

OneDigital Investment Advisors LLC increased its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 18.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 42,342 shares of the company's stock after acquiring an additional 6,511 shares during the period. OneDigital Investment Advisors LLC's holdings in Novo Nordisk A/S were worth $3,642,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. M. Kulyk & Associates LLC lifted its stake in Novo Nordisk A/S by 3.9% in the 4th quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after purchasing an additional 119 shares during the last quarter. Center for Financial Planning Inc. lifted its stake in Novo Nordisk A/S by 72.4% in the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after purchasing an additional 123 shares during the last quarter. Tradewinds Capital Management LLC lifted its stake in Novo Nordisk A/S by 2.6% in the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the last quarter. Exencial Wealth Advisors LLC lifted its stake in Novo Nordisk A/S by 0.5% in the 4th quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares during the last quarter. Finally, Indie Asset Partners LLC lifted its stake in Novo Nordisk A/S by 4.2% in the 4th quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock valued at $269,000 after purchasing an additional 126 shares during the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Stifel Nicolaus downgraded shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research note on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research note on Thursday, March 13th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research note on Friday. BMO Capital Markets reaffirmed a "market perform" rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a research note on Thursday, April 17th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday. Two research analysts have rated the stock with a sell rating, five have given a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of "Hold" and a consensus target price of $135.00.

Novo Nordisk A/S Trading Down 0.9 %

Shares of Novo Nordisk A/S stock traded down $0.56 on Friday, hitting $62.07. 7,826,465 shares of the company's stock traded hands, compared to its average volume of 6,109,718. Novo Nordisk A/S has a one year low of $57.00 and a one year high of $148.15. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. The company has a fifty day moving average of $73.62 and a two-hundred day moving average of $89.42. The company has a market capitalization of $278.54 billion, a price-to-earnings ratio of 18.87, a price-to-earnings-growth ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its earnings results on Wednesday, February 5th. The company reported $0.91 EPS for the quarter, beating the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The company also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Shareholders of record on Monday, March 31st were issued a $0.7874 dividend. The ex-dividend date of this dividend was Monday, March 31st. This represents a yield of 1.2%. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.